Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmaceutical Usefulness of Biopharmaceutics Classification System: Overview and New Trend

  • Received : 2010.09.07
  • Accepted : 2010.10.06
  • Published : 2010.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Since the introduction of the biopharmaceutics classification system (BCS) in 1995, it has viewed as an effective tool to categorize drugs in terms of prediction for bioavailability (BA) and bioequivalence (BE). The BCS consist of four drug categories: class I (highly soluble and highly permeable), class II (low soluble and highly permeable), class III (highly soluble and low permeable) and class IV (low soluble and low permeable), and almost all drugs belong to one of these categories. Likewise, classifying drugs into four categories according to their solubility and permeability is simple and relatively not controversial, and thus the FDA adopted the BCS as a science-based approach in establishing a series of regulatory guidance for the industry. Actually, many pharmaceutical companies have gained a lot of benefits, which directly connect to cost loss and failure decrease in the early stage of drug development. Recently, instead of solubility, using dissolution characteristics (e.g. intrinsic dissolution rate) have provided an improvement in the classification in correlating more closely with in vivo drug dissolution rather than solubility by itself. Furthermore, a newly modified-version of BCS, biopharmaceutics drug disposition classification system (BDDCS), which classify drugs into four categories according to solubility and metabolism, has been introduced and gained much attention as a new insight in respect with the drug classification. This report gives a brief overview of the BCS and its implication, and also introduces the recent new trend of drug classification.

Keywords

References

  1. Amidon, G.L., Higuchi, W.I., Ho, N.F., 1982. Theoretical and experimental studies of transport of micelle-solubilized solutes. J. Pharm. Sci. 71, 77-84. https://doi.org/10.1002/jps.2600710120
  2. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420. https://doi.org/10.1023/A:1016212804288
  3. Avdeef, A., 2001. Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem. 1, 277-351. https://doi.org/10.2174/1568026013395100
  4. Bergstrom, C.A., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., Artursson, P., 2003. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46, 558-570. https://doi.org/10.1021/jm020986i
  5. Dahlan, R., McDonald, C., Sunderland, V.B., 1987. Solubilities and intrinsic dissolution rates of sulphamethoxazole and trimethoprim. J. Pharm. Pharmacol. 39, 246-251. https://doi.org/10.1111/j.2042-7158.1987.tb06261.x
  6. Fleisher, D., Li, C., Zhou, Y., Pao, L.H., Karim, A., 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin. Pharmacokinet. 36, 233-254. https://doi.org/10.2165/00003088-199936030-00004
  7. Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. 2000. Available at http://www.fda.gov/cder/guidance/index.
  8. Jinno, J., Oh, D., Crison, J.R., Amidon, G.L., 2000. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J. Pharm. Sci. 89, 268-274. https://doi.org/10.1002/(SICI)1520-6017(200002)89:2<268::AID-JPS14>3.0.CO;2-F
  9. Lennernas, H., 1997. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 49, 627-638. https://doi.org/10.1111/j.2042-7158.1997.tb06084.x
  10. Lennernas, H., Knutson, L., Knutson, T., Hussain, A., Lesko, L., Salmonson, T., Amidon, G.L., 2002. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur. J. Pharm. Sci. 15, 271-277. https://doi.org/10.1016/S0928-0987(02)00005-2
  11. Lindenberg, M., Kopp, S., Dressman, J.B., 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur, J. Pharm. Biopharm. 58, 265-278. https://doi.org/10.1016/j.ejpb.2004.03.001
  12. Lobenberg, R., Amidon, G.L., Eur, J., 2000. Modern bioavail-ability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Pharm. Biopharm. 50, 3-12. https://doi.org/10.1016/S0939-6411(00)00091-6
  13. Martinez, M.N., Amidon, G.L., 2002. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42, 620-643. https://doi.org/10.1177/00970002042006005
  14. Papadopoulou, V., Valsami, G., Dokoumetzidis, A., Macheras, P., 2008. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. Int. J. Pharm. 361, 70-77. https://doi.org/10.1016/j.ijpharm.2008.05.021
  15. Rege, B.D., Yu, L.X., Hussain, A.S., Polli, J.E., 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J. Pharm. Sci. 90, 1776-1786. https://doi.org/10.1002/jps.1127
  16. Shargel, L., Wu-Pong, S., Yu, A., 2004. 5th edition, Chapter 15, Applied biopharmaceutics and pharmacokinetics.
  17. Sinko, P.J., Leesman, G.D., Amidon, G.L., 1991. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8, 979-988. https://doi.org/10.1023/A:1015892621261
  18. Tannergren, C., Knutson, T., Knutson, L., Lennernas, H., 2003. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55, 182-190. https://doi.org/10.1046/j.1365-2125.2003.01722.x
  19. Tannergren, C., Langguth, P., Hoffmann, K.J., 2001. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie. 56, 337-342
  20. Taub, M.E., Kristensen, L., Frokjaer, S., 2002. Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. Eur. J. Pharm. Sci. 15, 331-340. https://doi.org/10.1016/S0928-0987(02)00015-5
  21. van de Waterbeemd, H., 1998. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur. J. Pharm. Sci. 7, 1-3. https://doi.org/10.1016/S0928-0987(98)00051-7
  22. Wu, C.Y., Benet, L.Z., 2005. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23. https://doi.org/10.1007/s11095-004-9004-4
  23. Yu, L.X., Amidon, G.L., Polli, J.E., Zhao, H., Mehta, M.U., Conner, D.P., Shah, V.P., Lesko, L.J., Chen, M.L., Lee, V.H., Hussain, A.S., 2002. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19, 921-925. https://doi.org/10.1023/A:1016473601633
  24. Yu, L.X., Carlin, A.S., Amidon, G.L., Hussain, A.S., 2004. Feasibility studies of utilizingdisk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 270, 221-227. https://doi.org/10.1016/j.ijpharm.2003.10.016
  25. Yu, L.X., Carlin, A.S., Amidon, G.L., Hussain, A.S., 2004. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 11, 270, 221-227. https://doi.org/10.1016/j.ijpharm.2003.10.016
  26. Yu, L.X., Lipka, E., Crison, J.R., Amidon, G.L., 1996. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug. Deliv. Rev. 19, 359-376. https://doi.org/10.1016/0169-409X(96)00009-9
  27. Zakeri-Milani, P., Barzegar-Jalali, M., Azimi, M., Valizadeh, H., 2009a. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur. J. Pharm. Biopharm. 73, 102-106. https://doi.org/10.1016/j.ejpb.2009.04.015
  28. Zakeri-Milani, P., Valizadeh, H., Tajerzadeh, H., Islambulchilar, Z., 2009b. The utility of rat jejunal permeability for biopharmaceutics classification system. Drug. Dev. Ind. Pharm. 35, 1496-1502. https://doi.org/10.3109/03639040903037199
  29. Zakeri-Milani, P., Valizadeh, H., Tajerzadeh, H., Islambulchilar, Z., 2009c. The utility of rat jejunal permeability for biopharmaceutics classification system. Drug. Dev. Ind. Pharm. [Epub ahead of print].